Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 128, pseudogene (RNU6-128P)** is a human pseudogene derived from the U6 small nuclear RNA gene family. U6 small nuclear RNA (snRNA) is a critical component of the spliceosome complex involved in the splicing of pre-messenger RNA, but RNU6-128P is classified as a pseudogene, meaning it is not expected to produce a functional RNA or protein product[1][4]. As a pseudogene, RNU6-128P does not have known biological function, disease association, or relevance as a therapeutic target. **Clarification:** - The “pseudogene” annotation means RNU6-128P is not an active gene and does not produce a functional snRNA component[1][4]. - It is not a receptor, enzyme, transporter, or other typical drug target class. - No evidence was found for biological or disease roles, drug interactions, or use as a biomarker. - U6 snRNA is essential for splicing and broadly expressed, but *this specific pseudogene* is non-functional and not a therapeutic target[1][3][4]. - There is nothing obviously misspelled about the identifier, but it is critical to note it is a pseudogene and *not* a valid therapeutic or biological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 128, pseudogene (RNU6-128P).